Platinum is a key component of ovarian cancer systemic therapy. However, most patients will eventually face a recurrence, leading to chemotherapy resistance, especially against platinum. For individuals with platinum-resistant ovarian cancer (PROC), treatment options are limited, and their survival prospe...
Platinum is a key component of ovarian cancer systemic therapy. However, most patients will eventually face a recurrence, leading to chemotherapy resistance, especially against platinum. For individuals with platinum-resistant ovarian cancer (PROC), treatment options are limited, and their survival ...
Platinum-resistant recurrent ovarian cancer has a poor prognosis, but combined therapy with bevacizumab and anticancer agents may be useful. We report a patient with long-term disease control by the combination of bevacizumab and gemcitabine (BEV+GEM). The patient was a 77-year-old woman with ...
Targeting mitochondria have shown great potential for the treatment of platinum resistant ovarian cancer cells. Drugs targeting mitochondrial metabolism, such as metformin and 2-Deoxy-D-Glucose (2-DG), have demonstrated promising results in preclinical studies across various cancers, including ovarian canc...
1. Dorigo O, Patel S, Moser J, Frohlich M, Contag P. Safety and tolerability of CRX100, an NKT cell therapy combined with tumor-specific oncolytic vaccinia virus among patients with recurrent, platinum-resistant ovarian cancer. Presented at: SGO 2024 Annual Meeting on Women’s Cancer; March...
(EMT) in a carboplatin resistant ovarian cancer cell line by proteomics. This was validated in the platinum resistant versus sensitive parental cell lines, as well as platinum resistant versus sensitive human ovarian cancer patient samples. The prognostic significance of the different proteomics-...
The objective was to determine the response rate to platinum retreatment of "platinum-resistant" ovarian cancer after intervening nonplatinum therapy. We retrospectively identified 30 patients with platinum-resistant ovarian cancer who received nonplatinum chemotherapy for recurrent epithelial ovarian cancer pr...
Prolonged stabilization of platinum-resistant ovarian cancer in a single patient consuming a fermented soy therapy 来自 Semantic Scholar 喜欢 0 阅读量: 61 作者: Amber Klein a,Xiaoying He a,Maria Roche a,Allison Mallett a,Linda Duska b,Jeffrey G. Supko a,Michael V. Seiden a 展开 ...
Therapy of platinum-resistant cancerThe present invention concerns a method for treating platinum-resistant, ovarian cancer, primary peritoneal carcinoma or fallopian tube carcinoma with the combination of a HER2 antibody that effectively inhibits HER dimerization as well as gemcitabine.斯蒂芬·M·凯尔西...
Patients with platinum-resistant ovarian cancer have historically been an underserved population with few effective treatment options.